Prescribing information

 

Take a closer look at treatment outcomes and the types of patients who could benefit from ▼Beovu® (brolucizumab).

Treatment-Naïve

Treatment-naïve patient from the HAWK trial*1
Age:
89, Sex: Female, Race: Caucasian

 

Download the full patient case here

 

Silhoette of a female – Newly diagnosed female with wet AMD

Newly diagnosed female with wet AMD*1
Age:
87, Sex: Female, Race: Caucasian

Download the full patient case here

 

 

Previously Treated

Silhouette of a female – Real-world wet AMD patient who switched from another anti-VEGF

Real-world wet AMD patient who switched from another anti-VEGF*1
Age:
75, Sex: Female, Race: Caucasian

Download the full patient case here

 

*Certain identifiable information has been modified. Case is provided by treating physician and is not representative of whole patient population.

AMD, age-related macular degeneration; VEGF, vascular endothelial growth factor.

Reference

  1. Novartis data on file. BRODOF21-002, 2021.
Rate this content: 
No votes yet
UK | July 2021 | 139742
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]